|
Post # 1
|
||
Join Date: 27 Oct 2010
Location:  QatarPosts: 404 |
||
Walking more can cut diabetes risk |
||
|
Walking more can cut diabetes risk
10,000 steps urged LONDON, Jan 14, (AP): Walk more, and not only burn off calories, but also lessen the chance of becoming diabetic, a new study says. As part of a national study in Australia to measure diabetes levels, experts gave nearly 600 adults a pedometer to measure how many steps they took over two consecutive days in 2000 and again in 2005. Participants also completed a diet and lifestyle questionnaire and had their measurements — including height, weight and insulin sensitivity — taken. It was found that people who walked the most after five years not only had a lower body mass index, but were also more sensitive to insulin and less likely to develop diabetes. The study was paid for by the Australian government and pharmaceuticals groups who make diabetes drugs, including Abbott Australasia, AstraZeneca, Bristol-Myers Squibb. It was published Thursday in the journal BMJ. Many governments and health officials recommend people walk 10,000 steps a day, the equivalent of about five miles (eight kilometres). The study authors, from the Murdoch Children’s Research Institute in Melbourne, estimated that if a sedentary person increased their daily steps to reach the 10,000 step threshold, he or she would lower their body mass index by almost one point and improve their sensitivity to insulin by three times. Health officials have long suggested people stay slim and exercise to avoid diabetes. “Think about what you do each day and how you can work in more steps,†advises the American Diabetes Association on its website, which recommends taking the stairs instead of the elevator. “You’ll be amazed at how these extra minutes and steps add up.†Also: INDIANAPOLIS: Eli Lilly will pay Boehringer Ingelheim $387.4 million and collaborate with the German drugmaker to develop diabetes drugs with the US pharmaceutical company facing the expiration of some of its key patents. Lilly, based in Indianapolis, loses patent protection this year for its top-selling drug, the anti-psychotic Zyprexa, and faces the loss of some other key patents in the next few years. The drugmaker said Tuesday that the deal with Boehringer Ingelheim offers the potential of boosting near-term revenue. Lilly could receive more than $1 billion in future payments depending on how well the collaboration performs and whether the drugs under development reach certain sales milestones. Boehringer Ingelheim will be eligible for future payments totaling about $807 million. The collaboration includes two Lilly insulins expected to enter late-stage testing this year and a type 2 diabetes treatment from Boehringer Ingelheim that is being reviewed by regulators. Shares of Eli Lilly and Co. rose slightly in premarket trading. |
||